MedTrace Logo

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

NCT05041972 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-09-13

No results posted yet for this study

Summary

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/overexpressed Solid Tumors (ACE-Pan tumor-02)

Conditions

  • HER2 Mutation-Related Tumors
  • HER2 Amplified Solid Tumors

Interventions

DRUG

ARX788

ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).

Sponsors & Collaborators

  • Ambrx, Inc.

    lead INDUSTRY

Principal Investigators

  • Global Trial Lead · Ambrx, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2022-04-20
Completion
2022-04-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05041972 on ClinicalTrials.gov